🇺🇸 FDA
Pipeline program

REGN5459

R5459-ONC-1888

Phase 2 small_molecule completed

Quick answer

REGN5459 for Relapsed Multiple Myeloma is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Relapsed Multiple Myeloma
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials